CD19 and neoplasm: Clinical trials administering CD19-targeting CAR-T cell therapy that lacked endogenous TCR demmonstrated enhanced tumor recognition despite its missing receptor, suggesting the feasibility of adopting a universal CAR-T therapy for cancer treatment (118–120).